US Edition
News from MedCity News
If you want to know if MedCity News is credible or reliable, look no further. We rank MedCity News as High factuality. Find out more about our methodology here.
Media Bias Ratings
Average Bias Rating:
Center
Center
byAd Fontes MediaCenter
byMedia Bias/Fact CheckDo you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top MedCity News News
Medicare · United StatesDrugs that treat Type 2 diabetes, HIV and arthritis are among 15 new medications chosen for a Medicare drug price negotiation program that allows the federal government to haggle directly with drug manufacturers, the Trump administration said Tuesday.See the Story
Trump administration announces 15 new drugs for Medicare price negotiation program
77% Center coverage: 78 sources
ObesityRoche Holdings AG (OTC:RHHBY) on Tuesday released topline results from the CT388-103 Phase 2 trial of CT-388 for obesity. CT-388 is an investigational once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity, type 2 diabetes, and other obesity-related comorbidities. Trial Data The 469-patient trial was designed to evaluate the efficacy and safety of CT-388 at low, middle, and high doses. I…See the Story
Roche's Obesity Drug Helps Almost 87% People Lose At Least 10% Weight - Roche Holding (OTC:RHHBY)
67% Center coverage: 6 sources
